cIAP1 ligand 1 NEW
Price | $48 | $117 | $169 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-12 |
Product Details
Product Name: cIAP1 ligand 1 | CAS No.: 2095244-42-9 |
Purity: 98.77% | Supply Ability: 10g |
Release date: 2024/11/12 |
Product Introduction
Bioactivity
名稱 | cIAP1 ligand 1 |
描述 | cIAP1 ligand 1 (E3 ligase Ligand 12) is an apoptotic protein ligand based on the LCL161 derivative that recruits IAP ubiquitin ligases to degrade target proteins, and can be used in conjunction with androgen receptor ligands for the development of protein degradation agents that can be used in the study of prostate cancer. |
存儲條件 | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 80 mg/mL (133.61 mM), Sonication is recommended. |
關(guān)鍵字 | cIAP1 ligand 1 | cIAP-1 ligand 1 |
相關(guān)庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$97.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$0.00/1mg |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-08-26 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY